EUCTR2020-003267-26-DE进行中（未招募）1 期
A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and immunogenicity of a prophylactic SARS-CoV-2 RNA vaccine (BNT162b3) against COVID-19 using different dosing regimens in healthy adults - Phase I/II Trial Investigating the Safety and Effects of a BNT162 Vaccine Against COVID-19
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- BioNTech SE
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Have given informed consent by signing the informed consent form (ICF) before initiation of any trial-specific procedures.
- •2.They must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions (e.g., to practice social distancing and to follow good practices to reduce their chances of being infected or spreading COVID-19), and other requirements of the trial.
- •3.They must be able to understand and follow trial-related instructions.
- •4.For younger subject cohorts, volunteers must be aged 18 to 55 years, have a body mass index over 19 kg/m2 and under 30 kg/m2, and weigh at least 50 kg at Visit 0.
- •For older adult cohorts, volunteers must be aged 56 to 85 years, have a body mass index over 19 kg/m2 and under 30 kg/m2, and weigh at least 50 kg at Visit 0.
- •5.They must be healthy based on medical history, physical examination, 12-lead ECG, vital signs (systolic/diastolic blood pressure, pulse rate, body temperature, respiratory rate), and clinical laboratory tests (blood chemistry, hematology, and urine chemistry) at Visit 0.
- •6.Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin urine test at Visit 0 and Visit 1. Women that are postmenopausal or permanently sterilized will be considered as not having reproductive potential.
- •7.WOCBP must agree to practice a highly effective form of contraception during the trial, starting after Visit 0 and continuously until 60 d after receiving the last immunization.
- •8.WOCBP must confirm that they practiced at least one highly effective form of contraception for the 14 d prior to Visit 0.
- •9.WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting after Visit 0 and continuously until 60 d after receiving the last immunization.
- •10.Men who are sexually active with a WOCBP and have not had a vasectomy must agree to practice a highly effective form of contraception with their female partner of childbearing potential during the trial, starting after Visit 0 and continuously until 60 d after receiving the last immunization.
- •11.Men must be willing to refrain from sperm donation, starting after Visit 0 and continuously until 60 d after receiving the last immunization.
- •12.They must have confirmation of their health insurance coverage prior to Visit 0.
- •13.They must agree to not be vaccinated during the trial, starting after Visit 0 and continuously until 28 d after receiving the last immunization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 64
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 32
排除标准
- •Have had any acute illness, as determined by the investigator, with or without fever, within 72 h prior to any immunization. An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the investigator, the residual symptoms will not compromise their wellbeing if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
- •Have a known allergy, hypersensitivity, or intolerance to the planned IMP including any excipients of the IMP.
- •Had any medical condition or any major surgery (e.g., requiring general anesthesia) within the past 5 years which, in the opinion of the investigator, could compromise their wellbeing if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
- •Have any surgery planned during the trial, starting after Visit 0 and continuously until at least 90 d after receiving the last immunization.
- •Had any chronic use (more than 21 continuous days) of any systemic medications, including immunosuppressants or other immune-modifying drugs, within the 6 months prior to Visit 0 unless in the opinion of the investigator the medication would not prevent, limit, or confound the protocol-specified assessments or could compromise subject safety.
- •Note: Healthy participants with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 wks before enrollment, can be included.
- •Regular receipt of inhaled/nebulized corticosteroids.
- •Had any vaccination within the 28 d prior to Visit 0.
- •Had administration of any immunoglobulins and/or any blood products within the 3 months prior to Visit 0.
- •Had administration of another IMP including vaccines within 60 d or 5 half-lives (whichever is longer), prior to Visit 0.
- •Have a known history or a positive test of any of human immunodeficiency virus (HIV) 1 or 2, Hepatitis B, or Hepatitis C, within the 30 d prior to Visit 0.
- •Have a positive PCR-based test for SARS-CoV-2 within the 30 d prior to Visit 1.
- •Previously participated in an investigational trial involving lipid nanoparticles.
- •Have a history (within the past 5 years) of substance abuse or known medical, psychological, or social conditions which, in the opinion of the investigator, could compromise their wellbeing if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
- •Have a history of hypersensitivity or serious reactions to previous vaccinations.
- •Have a history of Guillain-Barré Syndrome within 6 wks following a previous vaccination.
- •Have a history of narcolepsy.
- •Have a history of or suspected immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination at Visit 0.
- •Have symptoms of the Coronavirus Disease 2019 (COVID-19), e.g., respiratory symptoms, fever, cough, shortness of breath and breathing difficulties.
- •Have had contact with persons diagnosed with COVID-19 or who tested positive for SARS-CoV-2 by any diagnostic test within the 30 d prior to Visit 1.
- •Are soldiers, persons in detention, CRO or sponsor staff or their family members.
- •Have a condition known to put them at high risk for severe COVID-19, including those with any of the following risk factors:
- •o COPD (chronic obstructive
研究者
相似试验
进行中（未招募）
1 期
Study to investigate the safety and effects of vaccines in adults.Protection against COVID-19MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001038-36-DEBioNTech SE638
招募中
1 期
CNT201 Phase 1/2 study in Adults with Dupuytren’s ContractureDupuytren’s ContractureHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12624000664549Connext Co., Ltd36
招募中
不适用
A Phase I/IIa (dose-escalation, single-center, open-label, Phase I and randomized, observer-blind, multi-center, placebo-controlled, Phase IIa) study to determine safety, tolerance and immunogenicity of a preventive COVID-19 vaccine ‘mRNA SARS-CoV-2 Vaccine (EG-COVID)’ in healthy adultKCT0006670Eyegene45
进行中（未招募）
不适用
A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer. - N/ADose-expansion study to assess safety, tolerability & efficacy:-One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma).-Two arms (phase II) to assess response in following breast cancer patients:1. HER2+ inoperable locally advanced or metastatic breast cancer.2. ER+ inoperable advanced/metastatic breast cancer progressed on at least 1 and received up to 3 lines of standard seq. endocrine therapy and who received up to 2 lines of cytotoxic therapy.EUCTR2006-002766-20-GBovartis Pharma Services AG
进行中（未招募）
1 期
A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in patients with either HER2 positive or ER positive locally advanced or metastatic breast cancer. - N/AEUCTR2006-002766-20-NLovartis Pharma Services AG